(Q40511063)

21 September 2017

title

Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein (English)

1 reference

21 September 2017

0 references

Maria P Rodriguez-Carreno

1

1 reference

21 September 2017

Michael S Nelson

2

1 reference

21 September 2017

Jason Botten

3

1 reference

21 September 2017

Kim Smith-Nixon

4

1 reference

21 September 2017

Michael J Buchmeier

5

1 reference

21 September 2017

J Lindsay Whitton

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

335

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

87-98

1 reference

Protection against mycoplasma infection using expression-library immunization

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

The phylogeny of New World (Tacaribe complex) arenaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: Generation, characterization, and cross-reactivity with other arenaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

A case of Lassa fever: experience at St Thomas's Hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Acute sensorineural deafness in Lassa fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Effective vaccine for lassa fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

The use of Lassa fever convalescent plasma in Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Lassa fever. Effective therapy with ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

DIALIGN 2: improvement of the segment-to-segment approach to multiple sequence alignment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

The nucleoprotein of Pichinde virus expressed by a vaccinia-Pichinde virus recombinant partially protects hamsters from lethal virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

SYFPEITHI: database for MHC ligands and peptide motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Multi-epitope DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Persistent infection of mice with Pichinde virus associated with failure to thrive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Protection by minigenes: a novel approach of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

Neonates mount robust and protective adult-like CD8(+)-T-cell responses to DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

DNA vaccination against persistent viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

7 January 2021

Pathogenesis of a Pichinde Virus Strain Adapted to Produce Lethal Infections in Guinea Pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

7 January 2021

Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

7 January 2021

DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

7 January 2021

Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.019

7 January 2021

10.1016/J.VIROL.2005.01.019

Identifiers

DOI

1 reference

21 September 2017

1 reference